Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q3 EPS of ($0.29), $0.09 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $45.89 million versus the consensus estimate of $37.52 million.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.